【摘要】 目的　初步探讨紫杉醇联合化疗治疗复发的晚期非小细胞肺癌的疗效。方法　 40例复治患者 ,每周紫杉醇方案 4例 ,紫杉醇 60mg/m2 静脉滴注 3h ,第 1、8、15天 ,顺铂 75mg/m2 第 2天 ,每 4周为一个周期 ;常规化疗 3 6例 ,紫杉醇 13 5mg/m2 静脉滴注 3h ,第 1天 ,顺铂 75mg/m2 或卡铂 3 0 0～ 3 5 0mg/m2 静脉输注第 2天 ,每 3～ 4周为一个周期 ,进行 2～ 4周期。结果　 40例患者中 3例死亡未评价疗效 ,1例因毒副反应未完成治疗 ,总有效率 13 .9% ( 5 / 3 6)。肿瘤相关症状改善率 5 8.3 % ( 2 1/ 3 6)。随访 2 7例 ,中位生存期 2 6.4周 ,1年生存率 8% ( 4 / 3 6)。主要毒副反应为骨髓抑制和肌肉、关节疼痛。结论　紫杉醇用于二线治疗有一定疗效并能改善症状 ,但给药方式及剂量仍需研究 ,二线治疗的地位尚需明确更多还原

【Abstract】 Objective To evaluate the activity and toxicity of paclitaxel as second line treatment for advanced non small cell lung cancer (NSCLC). Methods Forty patients with recurrent advanced NSCLC were enrolled. Thirty six patients were managed with regular regimen. Paclitaxel 135 mg/m 2, 3 h, on day 1; DDP 75 mg/m 2 or carboplatin 300 350 mg/m 2 on day 2. Four patients were managed with weekly regimen. Paclitaxel 60 mg/m 2,3 h, on days 1,8,15; DDP 75 mg/m 2 on day 2. It was repeated every three or four weeks, up to two to four cycles. Results Thirty six cases were evaluated for response and 27 for survival. The objective response rate was 13.9% (5/36). At least one tumor related symptom relief was observed in 21 patients (58.3%). The median survival duration was 26.4 weeks and 1 year survival rate was 8% (4/36). The main toxicities included myelosuppression, fatigue and myalgia arthralgia neuropathy. Conclusion Paclitaxel has advantage to be well tolerated and improve tumor related symptom. Further studies with standardization of dose and regimen will be needed to clarify its role in the second line treatment.更多还原